Bioavailability of melatonin in humans after day-time administration of D(7) melatonin - PubMed (original) (raw)

Clinical Trial

Bioavailability of melatonin in humans after day-time administration of D(7) melatonin

J B Fourtillan et al. Biopharm Drug Dispos. 2000 Jan.

Abstract

Absolute bioavailability of the neurohormone melatonin (MLT) was studied in 12 young healthy volunteers (six males, six females) after administration at midday, on two separate occasions, of 23 microg by intravenous (i.v.) infusion and 250 microg by oral solution of D(7) MLT, a molecule in which seven deuterium atoms replace seven hydrogen atoms. Exogenous (D(7)) and endogenous (D(0)) MLT were quantified simultaneously but separately by a highly specific assay: gas chromatography/negative ion chemical ionization mass spectrometry, developed in our laboratory, which enabled us to go down to 0.5 pg/mL in plasma samples. After i.v. administration, the maximum plasma concentration (C(max)) and the area under the plasma concentration-time curve (AUC) values were significantly different in male and female subjects, but there was no significant gender difference in total body clearance normalized to body weight: 1.27+/-0.20 L/h/kg and 1.18+/-0.22 L/h/kg for males and females, respectively. The apparent terminal half-life (t(1/2(z))) values were 36+/-2 and 41+/-10 min, respectively. After oral administration, pharmacokinetic parameters used to quantify bioavailability were near three-fold greater in female subjects than in males, with large inter-individual variations. The maximum plasma MLT concentration C(max)+/-S.D. was found at 243.7+/-124.6 pg/mL and 623.6+/-575.1 pg/mL for male and female subjects respectively, while the mean values for AUCs were 236+/-107 pg.h/mL and 701+/-645 pg.h/mL. The absolute bioavailability of MLT was from 1 to 37%: mean=8.6+/-3.9% and 16.8+/-12.7% for male and female subjects, respectively.

PubMed Disclaimer

Cited by

Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.
Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Talib WH, et al. Molecules. 2021 Apr 25;26(9):2506. doi: 10.3390/molecules26092506. Molecules. 2021. PMID: 33923028 Free PMC article. Review.
Updates on Nutraceutical Sleep Therapeutics and Investigational Research.
Yurcheshen M, Seehuus M, Pigeon W. Yurcheshen M, et al. Evid Based Complement Alternat Med. 2015;2015:105256. doi: 10.1155/2015/105256. Epub 2015 Jul 21. Evid Based Complement Alternat Med. 2015. PMID: 26265921 Free PMC article. Review.
Application of a validated HPLC-PDA method for the determination of melatonin content and its release from poly(lactic acid) nanoparticles.
Martins LG, Khalil NM, Mainardes RM. Martins LG, et al. J Pharm Anal. 2017 Dec;7(6):388-393. doi: 10.1016/j.jpha.2017.05.007. Epub 2017 May 20. J Pharm Anal. 2017. PMID: 29404064 Free PMC article.
Melatonin and the Brain-Heart Crosstalk in Neurocritically Ill Patients-From Molecular Action to Clinical Practice.
Bekała A, Płotek W, Siwicka-Gieroba D, Sołek-Pastuszka J, Bohatyrewicz R, Biernawska J, Kotfis K, Bielacz M, Jaroszyński A, Dabrowski W. Bekała A, et al. Int J Mol Sci. 2022 Jun 25;23(13):7094. doi: 10.3390/ijms23137094. Int J Mol Sci. 2022. PMID: 35806098 Free PMC article. Review.
Hit or miss: the use of melatonin supplements.
Goldstein CA, Burgess HJ. Goldstein CA, et al. J Clin Sleep Med. 2020 Dec 17;16(S1):29-30. doi: 10.5664/jcsm.8896. J Clin Sleep Med. 2020. PMID: 33054970 Free PMC article.

Bioavailability of melatonin in humans after day-time administration of D(7) melatonin - PubMed (original) (raw)